Literature DB >> 31023850

The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis.

Tim Rosenow1, L Clara Mok2, Lidija Turkovic2, Luke J Berry2, Peter D Sly3, Sarath Ranganathan4,5, Harm A W M Tiddens6, Stephen M Stick2,7,8.   

Abstract

INTRODUCTION: Pulmonary inflammation and infection are important clinical and prognostic markers of lung disease in cystic fibrosis (CF). However, whether in young children they are transient findings or have cumulative, long-term impacts on respiratory health is largely unknown. We aimed to determine whether their repeated detection has a deleterious effect on structural lung disease.
METHODS: All patients aged <6 years with annual computed tomography (CT) and bronchoalveolar lavage (BAL) were included. Structural lung disease on CT (%Disease) was determined using the PRAGMA-CF (Perth-Rotterdam Annotated Grid Morphometric Analysis for CF) method. The number of times free neutrophil elastase (NE) and infection were detected in BAL were counted, to determine cumulative BAL history. Linear mixed model analysis, accounting for repeat visits and adjusted for age, was used to determine associations.
RESULTS: 265 children (683 scans) were included for analysis, with BAL history comprising 1161 visits. %Disease was significantly associated with the number of prior NE (0.31, 95% CI 0.09-0.54; p=0.007) but not infection (0.23, 95% CI -0.01-0.47; p=0.060) detections. Reference equations were determined.
CONCLUSIONS: Pulmonary inflammation in surveillance BAL has a cumulative effect on structural lung disease extent, more so than infection. This provides a strong rationale for therapies aimed at reducing inflammation in young children.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31023850     DOI: 10.1183/13993003.01771-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

1.  Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV1, Lung Clearance Index and Peak Work Rate.

Authors:  Simone Gambazza; Alessandra Mariani; Anna Brivio; Federica Carta; Chiara Blardone; Saba Lisiero; Maria Russo; Carla Colombo
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

2.  Revealing the molecular signaling pathways of mucus stasis in cystic fibrosis.

Authors:  Susan E Birket; Steven M Rowe
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 3.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

4.  Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.

Authors:  Apparao B Kummarapurugu; Shuo Zheng; Abigail Pulsipher; Justin R Savage; Jonathan Ma; Bruce K Rubin; Thomas P Kennedy; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2021-02       Impact factor: 6.914

5.  Ivacaftor partially corrects airway inflammation in a humanized G551D rat.

Authors:  Morgan Green; Natalie Lindgren; Alexander Henderson; Johnathan D Keith; Ashley M Oden; Susan E Birket
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-07       Impact factor: 6.011

6.  Transport properties in CFTR-/- knockout piglets suggest normal airway surface liquid pH and enhanced amiloride-sensitive Na+ absorption.

Authors:  Roberta Benedetto; Raquel Centeio; Jiraporn Ousingsawat; Rainer Schreiber; Melanie Janda; Karl Kunzelmann
Journal:  Pflugers Arch       Date:  2020-07-25       Impact factor: 3.657

Review 7.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

Review 8.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

Review 9.  Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis.

Authors:  Giulio Cabrini; Alessandro Rimessi; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Paolo Pinton; Roberto Gambari
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

10.  Early Lung Disease Exhibits Bacteria-Dependent and -Independent Abnormalities in Cystic Fibrosis Pigs.

Authors:  Drake C Bouzek; Mahmoud H Abou Alaiwa; Ryan J Adam; Alejandro A Pezzulo; Leah R Reznikov; Daniel P Cook; Maria I Aguilar Pescozo; Patrick Ten Eyck; Chaorong Wu; Thomas J Gross; Douglas B Hornick; Eric A Hoffman; David K Meyerholz; David A Stoltz
Journal:  Am J Respir Crit Care Med       Date:  2021-09-15       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.